Source comparison
Best Peptides for Strength: Research-Grade Options Comparison
GHRP-2 + CJC-1295 (no-DAC) Pulsatile GH release via dual-axis stimulation (ghrelin + GHRH pathways) Direct. IGF-1 upregulation drives satellite cell activation and myofibrillar protein synthesis 100–200mcg GHRP-2 + 100mcg CJC-1295, 2–3x daily Subcutaneous inje
This comparison does not assign a generated winner or score.
- GHRP-2 + CJC-1295 (no-DAC)
- Pulsatile GH release via dual-axis stimulation (ghrelin + GHRH pathways)
- Direct. IGF-1 upregulation drives satellite cell activation and myofibrillar protein synthesis
- 100–200mcg GHRP-2 + 100mcg CJC-1295, 2–3x daily
- Subcutaneous injection
- Gold standard for strength research. Strongest evidence for contractile protein enhancement and motor unit recruitment gains
- MK-677 (Ibutamoren)
- Sustained GH/IGF-1 elevation via ghrelin receptor agonism
- Indirect. Hypertrophy-driven strength, secondary to lean mass accrual
- 10–25mg once daily
- Oral capsule or solution
- Best for long-duration protocols where compliance matters. Strength gains lag hypertrophy by 4–6 weeks
- Hexarelin
- Pulsatile GH release, cardioprotective effects via ghrelin pathway
- Direct. Similar to GHRP-2 but with additional cardiac muscle contractility benefits
- 100–200mcg 2–3x daily
- Underutilized in pure strength research. Cardiac benefits make it valuable for endurance-strength hybrid studies
- SLU-PP-332
- ERRγ agonism. Increases mitochondrial biogenesis and oxidative capacity
- Direct. Force output improvement independent of hypertrophy, mediated by ATP production per contraction
- 10–20mg daily (preclinical models)
- Oral or subcutaneous (formulation-dependent)
- Emerging compound with strongest data for strength-to-weight optimization. Limited human trial data as of 2026
- Follistatin-based peptides
- Myostatin inhibition. Removes negative regulation on muscle growth
- Indirect. Hypertrophy ceiling raised, allowing supraphysiological muscle mass accrual
- Protocol-dependent (ACE-031 trials used 1–3mg/kg)
- Subcutaneous or intramuscular injection
- High theoretical potential, limited by safety concerns in past trials. Strength gains are downstream of mass increases
- Cerebrolysin
- Neurotrophic signaling. Enhances synaptic plasticity and motor unit recruitment
- Indirect. Improved neuromuscular coordination and force transmission efficiency
- 5–30mL daily (clinical doses for neurological conditions)
- Intramuscular or intravenous injection
- Niche application for strength. Most valuable when neural adaptation is the limiting factor, not muscle size